Candid Therapeutics develops targeted therapies for autoimmune diseases, focusing on novel mechanisms of action. Their pipeline includes candidates designed to modulate immune pathways and improve patient outcomes. The company aims to address unmet clinical needs with scientifically validated drug candidates.
Funding
$370M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TC+1Founders
Product
Problem
Existing treatments for autoimmune diseases often fail to provide adequate relief, leaving a significant unmet need for effective therapies that can restore immune system balance. Current options may have limited efficacy or undesirable side effects, highlighting the need for more targeted and innovative approaches.
Solution
Candid Therapeutics develops targeted biologic therapies designed to address the root causes of autoimmune diseases by restoring immune system balance. The company utilizes advanced immunomodulatory techniques to create therapies that are more effective and have fewer side effects than existing treatments. By focusing on precision medicine, Candid Therapeutics aims to provide personalized treatment options that can significantly improve patient outcomes and quality of life. Their approach seeks to modulate the immune system in a way that promotes long-term remission and reduces the need for chronic immunosuppression.
Target Audience
The primary target audience includes individuals suffering from autoimmune diseases and the healthcare providers who treat them, such as rheumatologists, immunologists, and other specialists.
Features
- Development of targeted biologic therapies for autoimmune diseases
- Utilization of advanced immunomodulatory techniques
- Focus on restoring immune system balance
- Personalized treatment options for improved patient outcomes